Lipid Regulators Market – By Type (Statins [Branded, Combination], Non-statins [Fibric-acid Derivatives, Bile-acid]), By Indication (Hypercholesterolemia, Coronary Artery Disease), By Route of Administration, Distribution Channel & Forecast, 2024 – 2032

Lipid Regulators Market Size

Lipid Regulators Market was valued at USD 32.4 billion in 2023 and is set to register a CAGR of 3.8% from 2024 – 2032. The lipid regulators industry is experiencing growth driven by factors such as the rising prevalence of dyslipidemia and cardiovascular disease, advancements in drug development, increased prescription rate, and growing awareness of the importance of lipid management in reducing cardiovascular risk. Also, with the growing ageing population and increasing focus on preventive healthcare, the market is expected witness lucrative growth over the coming years.
 

For instance, according to World Population Prospects 2022, the population aged 65 years and above is expected to rise from 10% in 2022 to 16% in 2050. As the population ages, the risk of developing dyslipidemia and cardiovascular disease also increases, thereby driving the growth of the market.
 

Lipid regulators, also known as lipid-lowering agents or lipid-lowering drugs, are medications used to manage abnormal levels of lipids (fats) in the blood, primarily cholesterol and triglycerides. Elevated levels of these lipids are associated with an increased risk of cardiovascular diseases such as heart attacks and strokes. Lipid regulators can help lower cholesterol and triglyceride levels, reducing the risk of these diseases.
 

Lipid Regulators Market Trends

• Cardiovascular disease (CVD), including coronary artery disease, stroke, and peripheral artery disease, remains a leading cause of morbidity and mortality worldwide. For instance, according to World Health Organization, around 17.9 million people died from cardiovascular diseases which is almost 32% of all global deaths. Therefore, lipid regulators play a crucial role in managing cardiovascular diseases by targeting dyslipidemia, a major risk factor for CVD development and progression, thereby driving their demand in the market.
   
• In addition to this, pharmaceutical companies are investing in the development of novel lipid regulators with improved efficacy, safety, and tolerability profiles. Emerging therapies, such as PCSK9 inhibitors offer additional treatment option for patients with difficult-to-treat hypercholesterolemia and cardiovascular diseases. Thus, increasing adoption of such treatments supports the market expansion.
   

Lipid Regulators Market Analysis

The global market based on type is segmented into statins and non-statins. The statins segment dominated the global market in 2023 with 60.1% market share and is anticipated to grow at CAGR of 4.1% during the analysis period.
 

• Statins have become the standard of care for lipid management and cardiovascular risk reduction. They are recommended as first-line therapy in treatment guidelines issued by organizations such as the American College of Cardiology (ACC), thereby leading to widespread acceptance and adoption by healthcare providers.
   
• Owing to the factors such as their proven efficacy in lowering LDL cholesterol levels and reducing cardiovascular risk, wide acceptance, favorable safety profile and diverse range of products including both branded and generic formulations further propel the growth of this segment.

The market based on indication is categorized into hypercholesterolemia, hypertriglyceridemia, coronary artery disease, and other indications. The hypercholesterolemia segment accounted for highest market share and was valued at USD 13.1 billion in 2023.
 

• Hypercholesterolemia is highly prevalent globally, affecting millions of individuals across various age groups. The condition is particularly common in developed countries where diets are high. As a result, the sheer number of individuals with hypercholesterolemia drives the demand for lipid regulators, making it a dominant segment in the lipid regulators market.
   
• Furthermore, statins have demonstrated robust efficacy in lowering LDL cholesterol levels and reducing the risk of cardiovascular events in individuals with hypercholesterolemia. Thus, the support in treatment guidelines results in widespread adoption and prescription of statins for hypercholesterolemia management.
   

The market based on route of administration is classified into oral and injectable. The oral segment held highest market share in 2023 and is anticipated to be valued at USD 37.3 billion by 2032.
 

• Lipid regulators are predominantly administered orally. Most lipid regulators, including statins, fibrates, bile acid sequestrants, ezetimibe, and nicotinic acid derivatives, are available in oral formulations. Also, oral administration is preferred due to its convenience, patient acceptance, and ease of self-administration, contributing to the adoption rate of oral lipid regulators in clinical practice.
   
• Further factors such as wide availability, established efficacy, flexible dosing, and cost-effectiveness collectively reinforce the prominence of oral segment in the global market.
   

Global market based on distribution channel into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held majority of market share and is projected to grow at 3.7% CAGR from 2024 – 2032.
 

• Hospital pharmacies dominate the overall market due their central role in medication management, coupled with their clinical expertise.
   
• Also, a diverse patient population with cardiovascular conditions, and availability of wide range of lipid regulatory drugs is expected to further augment the market growth.

North America lipid regulators market accounted for USD 13.6 billion revenue in 2023 and is projected to reach USD 18.1 billion by 2032.
 

• North America region faces a significant burden of cardiovascular disease. Unhealthy dietary habits, sedentary lifestyles, obesity, and other lifestyle factors contribute to the widespread occurrence of CVD especially dyslipidemia in the population. It is a major risk factor for coronary artery disease, stroke, and peripheral artery disease, necessitating the widespread use of lipid regulator therapies in the region.
   
• Furthermore, advanced healthcare infrastructure, a robust pharmaceutical industry, favorable regulatory policies, supportive reimbursement schemes, and increasing awareness collectively contributes to the North America market demand.
   

Lipid Regulators Market Share

The lipid regulators industry is dynamic and multifaceted, characterized by several key players and a diverse range of lipid regulators. Competition in the global market is influenced by factors such as drug efficacy, safety, pricing, marketing strategies, and regulatory approvals. Companies strive to differentiate their products through clinical advancements, novel mechanisms of action, and strategic partnerships to gain market share and maintain a competitive edge in this dynamic and rapidly evolving market.
 

Lipid Regulators Market Companies

Prominent players operating in the lipid regulators industry include:

• AbbVie Inc
• Amgen Inc.
• AstraZeneca plc
• Bristol-Myers Squibb
• Dr. Reddy's Laboratories Ltd.
• Merck & Co.
• Novartis AG
• Pfizer, Inc.
• Sanofi
• Teva Pharmaceuticals
   

Lipid Regulators Industry News:

• In July 2023, U.S. FDA approved expanded indication for Leqvio (inclisiran) by Novartis to include treatment of adults with high LDL-C and who are at increased risk of heart disease. This approval is expected to enhance their product offering and revenue growth.
   
• In May 2022, Sun Pharmaceutical Industries Ltd. launched Brillo, a bempedoic acid in India for reducing low-density lipoprotein (LDL) cholesterol. This strategic initiative helped the company to strengthen its product portfolio and boost its revenue.
   

The lipid regulators market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Statins          
  • Branded statins
  • Statin combination
  • Generic statins 
• Non-statins   
  • Fibric-acid derivatives
  • Bile-acid sequestrants
  • Ezetimibe
  • Nicotinic acid derivatives
  • PCSK9 inhibitors
  • Other non-statins

Market, By Indication

• Hypercholesterolemia
• Hypertriglyceridemia
• Coronary artery disease
• Other indications

Market, By Route of Administration

• Oral
• Injectable

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa